CNBC Daily Open: Even if the U.S. Supreme Court rules tariffs illegal, the case for them might not be closed

Treasury Secretary Scott Bessent stated that the U.S. government possesses "other authorities" to uphold Trump-era tariffs, including the Smoot-Hawley Act, even if the Supreme Court rules against them, signaling persistent trade policy uncertainty. Separately, Norway's Equinor pledged nearly $1 billion to crisis-stricken Orsted's rights issue, indicating strong confidence in the offshore wind sector. Concurrently, Novo Nordisk's weight-loss drug Wegovy demonstrated superior heart attack risk reduction compared to Eli Lilly's rival, driving its stock higher, while European aerospace and defense stocks gained significantly following a major warship order from Norway.

Analysis

The market is navigating a complex set of cross-currents, with significant developments in trade policy, pharmaceuticals, and industrials. In the U.S., persistent trade policy uncertainty is signaled by Treasury Secretary Scott Bessent's comments affirming the administration's intent to uphold Trump-era tariffs using alternative authorities like the Smoot-Hawley Act, even if the Supreme Court rules against them. While U.S. futures remained flat, suggesting a 'wait-and-see' approach, this signals a lingering risk for trade-sensitive sectors. In Europe, the aerospace and defense sector is showing notable strength, with its Stoxx index rising 2.2% on the back of a £10 billion Norwegian warship order, significantly outperforming the broader market's 0.23% gain. Within the pharmaceutical space, Novo Nordisk (NVO) has gained a competitive edge as its drug Wegovy demonstrated superior heart attack risk reduction compared to Eli Lilly's (LLY) Tirzepatide, causing NVO shares to climb 1.76%. Finally, in the renewable energy sector, Norwegian oil major Equinor (EQNR) has signaled strong confidence in offshore wind by pledging nearly $1 billion in a rights issue for the crisis-stricken developer Orsted (ORSTED), suggesting a belief in the sector's long-term viability despite current headwinds.

Key Decisions for Investors

• Given the U.S. Treasury's commitment to maintaining tariffs regardless of court rulings, investors should remain cautious on sectors with high exposure to international trade and monitor for any escalation in legal or policy actions.
• The superior clinical trial results for Novo Nordisk's Wegovy over Eli Lilly's competing drug reinforce NVO's leadership in the weight-loss market, warranting a portfolio review to potentially increase exposure to NVO while monitoring the competitive response from LLY.
• Equinor's substantial capital injection into Orsted provides a strong vote of confidence in the long-term fundamentals of the offshore wind sector, suggesting that Orsted's current distress could represent a strategic opportunity for investors with a high risk tolerance and a long-term horizon.
• The significant outperformance of the European aerospace and defense index, fueled by large-scale government contracts, indicates robust sector-specific tailwinds, making it prudent to assess opportunities for increased allocation to capitalize on heightened geopolitical spending.